What is LOPJLB’s current signal on FATE?

LOPJLB’s latest quantitative signal on Fate Therapeutics, Inc. (FATE) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is FATE in?

Fate Therapeutics, Inc. (FATE) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Fate Therapeutics, Inc. (FATE) do?

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute…

Fate Therapeutics, Inc. (FATE)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$2.00-6.10%Close

SELLCRISIS · day 5

Company news

globenewswire.com · 12d ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 13d ago

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

defenseworld.net · 15d ago

CIRM backs Fate’s FT819 lupus trial

globenewswire.com · 19d ago

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

globenewswire.com · 28d ago

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

globenewswire.com · 35d ago

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

globenewswire.com · 41d ago

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

defenseworld.net · 41d ago

BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE

seekingalpha.com · 42d ago

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

globenewswire.com · 61d ago

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

zacks.com · 62d ago

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

globenewswire.com · 62d ago

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

youtube.com · 70d ago

FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says

globenewswire.com · 72d ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Market news & ticker search · RSS for FATE

FAQ

What is LOPJLB’s current signal on FATE?: LOPJLB’s latest quantitative signal on Fate Therapeutics, Inc. (FATE) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is FATE in?: Fate Therapeutics, Inc. (FATE) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Fate Therapeutics, Inc. (FATE) do?: Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute…

Fate Therapeutics, Inc. (FATE)

Key stats

Industry peers

Prediction markets

Company news

FAQ